Navigation Links
Trillium and Biogen Idec enter into global license agreement
Date:1/12/2010

biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, TTI-1612, is a recombinant growth factor that is being developed for the treatment of interstitial cystitis (IC) and the prevention of necrotizing enterocolitis (NEC). Trillium has broad portfolio preclinical immunology programs, including two that target the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. In addition, the company has an FcyRlla-specific humanized monoclonal antibody in development for treatment of immune complex-mediated inflammatory diseases.

The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. The Company is supported by three premier venture capital investors: Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.

SOURCE Trillium Therapeutics Inc.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
2. Trillium Strengthens its Board of Directors
3. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
4. Biogenerics Will Save Billions, Says Hospira CEO
5. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
6. Icahn Confirms Intention to Nominate Three Directors at Biogen
7. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
8. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
9. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2015)... , April 23, 2015  The Heinz ... 20 th Heinz Awards, which will present ... exceptional Americans for their creativity and determination in ... abroad. This year,s recipients include a ... of modern-day life and personal relationships; two former ...
(Date:4/22/2015)... MINNEAPOLIS, MN , April 22, 2015 /PRNewswire/ - ... results for the first quarter 2015 on Thursday, May ... company has scheduled a webcast and conference call for ... results. Live audio of the conference ... be available to investors, members of the news media ...
(Date:4/22/2015)... 2015 Today, DuPont announced it ... leading microbiome discovery company. This acquisition will build ... in both seed and crop protection to discover ... , “In 2014, the businesses in DuPont’s ... sold more than $1 billion in biological solutions ...
(Date:4/22/2015)... Va. , April 22, 2015 ... TowerView Health was the winner of the 9th annual ... Fifteen startup companies were selected to deliver live ... industry leaders, as part of HIMSS15 held last week ... more than 43,000 health IT professionals and 1,200 exhibiting ...
Breaking Biology Technology:From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 4From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 5From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 6BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2DuPont Acquires Taxon Biosciences, Inc. 2DuPont Acquires Taxon Biosciences, Inc. 3DuPont Acquires Taxon Biosciences, Inc. 4TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 2TowerView Health Named Venture+ Forum Pitch Competition Winner At HIMSS15 3
... Fla., Aug. 7 Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) ... 30, 2009. , , Second Quarter 2009 ... 30, 2009, the Company reported a net loss of $1,761,887, or $0.13 per ... per basic and diluted share for the same period in 2008. Second quarter ...
... , BRISBANE, Calif., Aug. 7 InterMune, Inc. (Nasdaq: ... Executive Officer and President of InterMune, will present at the Canaccord ... 2009 at 10:30 a.m. EDT. , , To ... interested parties may log on to the investor relations page of ...
... , , , ... Genetics (Pink Sheets: VRAL) has formed a wholly owned subsidiary ... technology developed by University of Colorado Professor M. Karen Newell ... tumor cell,s ability to generate energy from glucose or from ...
Cached Biology Technology:Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 7Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... in German . Medicines from plants ... However, that has nothing in common with what the ... Applied Ecology IME in Aachen, Germany, are doing. They ... unlike many other medications, cannot be chemically produced. ...
... ,A pan-European study of 755 gout patients found that prevalence ... lowest in France (0.76%). French, German and British gout patients ... work and social impairment compared to controls (p , Abstract ... efficacy and safety of pegloticase (Krystexxa) , Results of ...
... that the HPV vaccine did not have significant effects on ... with inactive SLE receiving stable doses of medications after administration, ... in this group of patients. SLE, an autoimmune disorder, affects ... shown that the rate of HPV in this group is ...
Cached Biology News:Medicines from plants 2Several abstracts on gout reveal true burden of disease and highlight promising new treatments 2Study shows the HPV vaccine Gardasil doesn't increase disease activity in SLE patients 2
Glutathione Agarose Beads 10 ml...
...
...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
Biology Products: